

Paraneoplastic, Autoantibody Evaluation, Spinal Fluid

Test ID: PAC1

Explanation:

On the effective date this test will become obsolete. In its place, ordering a comprehensive neurological phenotype-specific autoimmune/paraneoplastic evaluation (e.g., encephalopathy, movement disorders, myelopathy, axonal neuropathy, etc.) should be considered.

The recommended alternative, based on patient presentation, is noted below. Additional alternatives may be required depending on patient phenotype. Consult our [autoimmune neurology test menu](#) for more details.

Note: As the field of autoimmune neurology evolves, antibodies once dismissed as rare or of unclear significance are now understood to identify treatable disorders — still uncommon but likely underrecognized. These antibodies are seldom included in nonspecific, traditional paraneoplastic evaluations. Our phenotype-specific evaluations include both autoimmune and paraneoplastic antibodies to make it easy for physicians to order the correct evaluation based on clinical presentation and feel confident they are getting a complete picture of their patient's condition. [Learn more here.](#)

Please consider sharing this information with frequent PAC1 users throughout the institution.

Recommended Alternative Test:

Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

Test ID: ENC2

Useful For:

Suspected central nervous system (CNS) immune-mediated disorders.

[ENC2 - Overview: Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid](#)

Questions

Contact Amy Ennis or Steven Monson, Laboratory Resource Coordinator at 800-533-1710.